Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 69% Improvement Relative Risk Ivermectin  Hariyanto et al.  META ANALYSIS c19ivm.org Favors ivermectin Favors control

Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies

Hariyanto et al., Reviews In Medical Virology, doi:10.1002/rmv.2265
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19ivm.org
Systematic review and meta analysis of 19 RCTs showing mortality RR 0.31 [0.15-0.62].
7 meta analyses show significant improvements with ivermectin for mortality Bryant, Hariyanto, Kory, Lawrie, Nardelli, Zein, hospitalization Schwartz, recovery Kory, and cases Kory.
Currently there are 102 ivermectin for COVID-19 studies, showing 49% lower mortality [35‑60%], 29% lower ventilation [12‑42%], 35% lower ICU admission [7‑54%], 34% lower hospitalization [20‑45%], and 81% fewer cases [71‑87%].
risk of death, 69.0% lower, RR 0.31, p = 0.001.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hariyanto et al., 6 Jun 2021, peer-reviewed, 5 authors.
This PaperIvermectinAll
Ivermectin and outcomes from Covid‐19 pneumonia: A systematic review and meta‐analysis of randomized clinical trial studies
Timotius Ivan Hariyanto, Devina Adella Halim, Jane Rosalind, Catherine Gunawan, Andree Kurniawan
Reviews in Medical Virology, doi:10.1002/rmv.2265
Ivermectin is an FDA-approved drug for a parasitic disease that has broad antiviral activity. This study aims to analyse the efficacy of ivermectin in improving the Covid-19 outcomes. We systematically searched the PubMed, Europe PMC and ClinicalTrials.gov database using specific keywords related to our aims until 10th May 2021. All published randomized clinical trial studies on Covid-19 and ivermectin were retrieved. The quality of the study was assessed using Jadad scale assessment tool for clinical trial studies. Statistical analysis was done using Review Manager 5.4 software. A total of 19 studies with 2768 Covid-19 patients were included in this meta-analysis. This meta-analysis showed that ivermectin was associated with reduction in severity of Covid-19 (RR 0.43 [95% CI 0.23-0.81], p = 0.008), reduction of mortality (RR 0.31 [95% CI 0.15-0.62], p = 0.001), higher negative RT-PCR test results rate (RR 1.23 [95% CI 1.01-1.51], p = 0.04), shorter time to negative RT-PCR test results (mean difference [MD] −3.29 [95% CI −5.69, −0.89], p = 0.007), higher symptoms alleviations rate (RR 1.23 [95% CI 1.03−1.46], p = 0.02), shorter time to symptoms alleviations (MD −0.68 [95% CI −1.07, −0.29], p = 0.0007) and shorter time to hospital discharge (MD −2.66 [95% CI −4.49, −0.82], p = 0.004). Our study suggests that ivermectin may offer beneficial effects towards Covid-19 outcomes. More randomized clinical trial studies are still needed to confirm the results of our study.
CONFLICT OF INTEREST The Authors declare that there is no conflict of interest. AUTHORS CONTRIBUTION Conceptualization
References
Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.191
Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos, QJM, doi:10.1093/qjmed/hcab035
Banerjee, Nandy, Dalai, Ahmed, The battle against COVID 19 pandemic: what we need to know before we "test fire" ivermectin, Drug Res (Stuttg), doi:10.1055/a-1185-8913
Bukhari, Asghar, Perveen, Efficacy of ivermectin in COVID-19 patients with mild to moderate disease, medRxiv, doi:10.1101/2021.02.02.21250840
Buonaguro, Ascierto, Morse, Covid-19: time for a paradigm change, Rev Med Virol, doi:10.1002/rmv.2134
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res, doi:10.1016/j.antiviral.2020.104787
Canga, Prieto, Liébana, The pharmacokinetics and interactions of ivermectin in humans--a mini-review, AAPS J, doi:10.1208/s12248-007-9000-9
Chaccour, Casellas, Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, doi:10.21203/rs.3.rs-116547/v1
Chachar, Khan, Asif, Khushbakht, Khaqan et al., Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci, doi:10.18483/ijSci.2378
Chowdhury, Shahbaz, Karim, Islam, Guo et al., A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients, EJMO, doi:10.21203/rs.3.rs-38896/v1
Elgazzar, Hany, Youssef, Hafez, Moussa et al., Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic, doi:10.21203/rs.3.rs-100956/v2
Elsawah, Elsokary, Abdallah, Elshafie, Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis, Rev Med Virol, doi:10.1002/rmv.2187
Gonzalez, Gamez, Enciso, Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial, doi:10.1101/2021.02.18.21252037
Götz, Magar, Dornfeld, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep, doi:10.1038/srep23138
Harapan, Itoh, Yufika, Coronavirus disease 2019 (COVID-19): a literature review, J Infect Public Health, doi:10.1016/j.jiph.2020.03.019
Hariyanto, Christian, Kurniawan, Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis, South Afr J HIV Med, doi:10.4102/sajhivmed.v22i1.1220
Hariyanto, Halim, Gunawan, Kurniawan, Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies, Rev Med Virol
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, Clin Exp Pharmacol Physiol, doi:10.1111/1440-1681.13488
Hariyanto, Hardyson, Kurniawan, Efficacy and safety of tocilizumab for coronavirus disease 2019 (Covid-19) patients: a systematic review and meta-analysis, Drug Res (Stuttg), doi:10.1055/a-1336-2371
Hariyanto, Japar, Kwenandar, Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis, Am J Emerg Med, doi:10.1016/j.ajem.2020.12.076
Hariyanto, Kurniawan, Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection, Transfus Apher Sci, doi:10.1016/j.transci.2020.102926
Hariyanto, Kurniawan, Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression, J Diabetes Metab Disord, doi:10.1007/s40200-021-00777-4
Hariyanto, Kurniawan, Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.07.044
Hariyanto, None
Hariyanto, None
Hariyanto, Prasetya, Kurniawan, Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection, Dig Liver Dis, doi:10.1016/j.dld.2020.10.001
Hariyanto, Putri, Situmeang, Kurniawan, Dementia is associated with severe coronavirus disease 2019 (COVID-19) infection, Am J Med Sci, doi:10.1016/j.amjms.2020.10.026
Hariyanto, Rizki, Kurniawan, Anosmia/Hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis, Int Arch Otorhinolaryngol, doi:10.1055/s-0040-1719120
Hashim, Maulood, Rasheed, Fatak, Kabah et al., Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq, doi:10.1101/2020.10.26.20219345
Huang, Wang, Chen, Song, Liu et al., Perioperative antibiotics to prevent acute endophthalmitis after ophthalmic surgery: a systematic review and meta-analysis, PLoS One, doi:10.1371/journal.pone.0166141
Jadad, Moore, Carroll, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Contr Clin Trials, doi:10.1016/0197-2456(95)00134-4
Kishoria, Mathur, Parmar, Ivermectin as adjuvant to hydroxychloroquine in patients resistant to standard treatment for sars-cov-2: results of an open-label randomized clinical study. Paripex, -Indian J Res, doi:10.36106/paripex
Kwenandar, Japar, Damay, Coronavirus disease 2019 and cardiovascular system: a narrative review, Int J Cardiol Heart Vasc, doi:10.1016/j.ijcha.2020.100557
López-Medina, López, Hurtado, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, J Am Med Assoc, doi:10.1001/jama.2021.3071
Mahmud, Rahman, Alam, Clinical trial of ivermectin plus doxycycline for the treatment of confirmed covid-19 infection
Mohan, Tiwari, Suri, Ivermectin in mild and moderate COVID-19 (RIVETCOV): a randomized, placebo-controlled trial, doi:10.21203/rs.3.rs-191648/v1
Mudatsir, Fajar, Wulandari, Predictors of COVID-19 severity: a systematic review and meta-analysis, doi:10.12688/f1000research.26186.2
Mulchandani, Lyngdoh, Kakkar, Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis, Eur J Clin Invest, doi:10.1111/eci.13429
Niaee, Gheibi, Namdar, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial, doi:10.21203/rs.3.rs-109670/v1
Okumuş, Demirtürk, Çetinkaya, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect Dis, doi:10.1186/s12879-021-06104-9
Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a singlecentre, open-label, randomized controlled study, IMC J Med Sci
Pott-Junior, Paoliello, Miguel, Use of ivermectin in the treatment of Covid-19: a pilot trial, Toxicol Rep, doi:10.1016/j.toxrep.2021.03.003
Putri, Hariyanto, Hananto, Christian, Situmeang et al., meta-analysis, and meta-regression
Ravikitri, Pattadar, Raj, Ivermectin as a potential treatment for mild to moderate COVID-19-a double blind randomized placebo-controlled trial, medRxiv, doi:10.1101/2021.01.05.21249310
Rodriguez-Morales, Cardona-Ospina, Ocampo, Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis, Trav Med Infect Dis, doi:10.1016/j.tmaid.2020.101623
Shahbaznejad, Davoudi, Eslami, Effect of ivermectin on COVID-19: a multicenter double-blind randomized controlled clinical trial, Clin Ther, doi:10.1016/j.clinthera.2021.04.007
Shouman, Nafae, Ragab, Use of Ivermectin as a prophylactic option in asymptomatic family close contacts for patients with COVID-19
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir Res, doi:10.1016/j.antiviral.2013.06.002
Terrin, Schmid, Lau, Olkin, Adjusting for publication bias in the presence of heterogeneity, Stat Med, doi:10.1002/sim.1461
Thornton, Lee, Publication bias in meta-analysis: its causes and consequences, J Clin Epidemiol, doi:10.1016/s0895-4356(99)00161-4
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/BJ20120150
Wan, Wang, Liu, Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC Med Res Methodol, doi:10.1186/1471-2288-14-135
Yan, Ci, Chen, Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, doi:10.1007/s00011-011-0307-8
Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit